Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy

Summary

We previously developed a novel non-trans thoracic esophagectomy, the single-port inflatable mediastinoscopy combined with laparoscopy for the radical esophagectomy of esophageal cancer.This study is evaluating the feasibility and safety of radical resection of single-port inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, as well as the clinical value of the radical resection of single-port inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma as a new minimally invasive operation for esophageal carcinoma.

Conditions

• Esophageal Cancer

Interventions

PROCEDURE

Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery

Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in "Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer" J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11.

PROCEDURE

Thoracoscopy Combined With Laparoscopic Surgery

Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery

Sponsors & Collaborators

• General Hospital of Ningxia Medical University

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Shanghai Chest Hospital

  collaborator OTHER

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• Changzhi Medical College

  collaborator OTHER

• Zhangzhou Affiliated Hospital of Fujian Medical University

  collaborator OTHER

• Harbin Medical University

  collaborator OTHER

• Hubei Cancer Hospital

  collaborator OTHER

• Jining First People's Hospital

  collaborator OTHER

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Fifth Affiliated Hospital, Sun Yat-Sen University

  lead OTHER

Principal Investigators

• Liu Shaoxuan · Office of clinical research center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-11-11

Primary Completion

2027-12-28

Completion

2028-12-28

Countries

• China

Study Locations